Login to Your Account

China’s Heavyweight Pharma Goes Private, and into Biotech

By Kristine Yang
Contributing Writer

Wednesday, September 11, 2013
SHANGHAI – When it went public in April 2007, Simcere Pharmaceutical Group quickly became the largest Chinese pharmaceutical listed in the U.S. Despite a good early performance, the stock never lived up to its promise. The firm’s share price crashed to below $5 after the global financial crisis and has been lingering at below $10 since late 2011 . Simcere, originally a maker of generics that has expanded into biologicals, will go private before the end of the year.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription